Longitudinal effects of selective serotonin reuptake inhibitor therapy and cytokine-related depression on hepatitis c viral logs during antiviral therapy

Journal of Clinical Psychopharmacology

Volumn 34, Issue 1, 2014, Pages 80-84

  Sims, Omar T ^a   Whalen, Christopher C ^b   Nackerud, Larry G ^c   Bride, Brian E ^c  

^a UNIVERSITY OF ALABAMA   (United States)

^b Department of Epidemiology and Biostatistics   (United Kingdom)

^c UNIVERSITY OF GEORGIA   (United States)

Author keywords

Antidepressants; Cytokine related depression; Hepatitis C; Sustained virological response

Indexed keywords

INTERFERON; PEGINTERFERON; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR; VIRUS RNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CYTOKINE RELATED DEPRESSION; DEPRESSION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CYTOKINES; DEPRESSION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INFLAMMATION MEDIATORS; INTERFERONS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84891747510     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182a47397     Document Type: Article

References (34)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558-567.
2. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3:47-52.
3. NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements. 2002;19:1-46.
4. Krueger C, Hawkins K, Wong S, et al. Persistent pro-inflammatory cytokines following the initiation of pegylated IFN therapy in hepatitis C infection is associated with treatment-induced depression. J Viral Hepat. 2011;18:e284-e291.
5. Kraus MR, Al-Taie O, Schafer A, et al. Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology. 2007;132:1279-1286.
6. Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol. 2002;22:86-90.
7. Evon DM, Ramcharran D, Belle SH, et al. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the VIRAHEP-C study. Am J Gastroenterol. 2009;104:2949-2958.
8. Evon DM, Verma A, Simpson K, et al. Psychiatric symptoms during interferon treatment for hepatitis C: experiences from a tertiary care hepatology centre. Aliment Pharmacol Ther. 2008;27:1071-1080.
9. Fontana RJ, Kronfol Z, Lindsay KL, et al. Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. Am J Gastroenterol. 2008;103:2766-2775.
10. Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in ''difficult-to-treat'' psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology. 2007;46:991-998.
11. Raison CL, Demetrashvili M, Capuron L, et al. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19:105-123.
12. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7:942-947.
13. Rotman Y, Borg BB, Soza A, et al. Low-and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response. Aliment Pharmacol Ther. 2010;31:1018-1027.
14. Raison CL, Borisov AS, Broadwell SD, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry. 2005;66:41-48.
15. Galvao-de Almeida A, Guindalini C, Batista Neves S, et al. Can antidepressants prevent interferon-alpha-induced depression? A review of the literature. Gen Hosp Psychiatry. 2010;32:401-405.
16. Morasco BJ, Loftis JM, Indest DW, et al. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Psychosomatics. 2010;51: 401-408.
17. Sockalingam S, Abbey S. Managing depression during hepatitis C treatment. Can J Psychiatry. 2009;54:614-625.
18. Nelligan JA, Loftis JM, Matthews AM, et al. Depression comorbidity and antidepressant use in veterans with chronic hepatitis C: results from a retrospective chart review. J Clin Psychiatry. 2008;69:810-816.
19. Baraldi S, Hepgul N, Mondelli V, et al. Symptomatic treatment of interferon-alphaYinduced depression in hepatitis C: a systematic review. J Clin Psychopharmacol. 2012;32:531-543.
20. Robaeys G, Wichers MC, De Bie J, et al. Does antidepressant medication in patients with hepatitis C undergoing interferon alpha treatment reduce therapeutic efficacy? Gut. 2009;58:145; author reply 145-146.
21. Raison CL, Broadwell SD, Borisov AS, et al. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun. 2005;19:23-27.
22. Maddock C, Landau S, Barry K, et al. Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response. Mol Psychiatry. 2005;10:332-333.
23. Schafer A, Scheurlen M, Weissbrich B, et al. Sustained virological response in the antiviral therapy of chronic hepatitis C: is there a predictive value of interferon-induced depression? Chemotherapy. 2007;53:292-299.
24. Loftis JM, Socherman RE, Howell CD, et al. Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett. 2004;365:87-91.
25. Raison CL, Woolwine BJ, Demetrashvili MF, et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther. 2007;25:1163-1174.
26. Gupta R, Kumar R, Bassett M. Interferon-induced depressive illness in hep C patients responds to SSRI antidepressant treatments. Neuropsychiatr Dis Treat. 2006;2:355-358.
27. Klein MB, Cooper C, Brouillette MJ, et al. CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy. Contemp Clin Trials. 2008;29: 617-630.
28. Dan AA, Martin LM, Crone C, et al. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol. 2006;44: 491-498.
29. Garcia-Tsao G, Lim JK ,Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol. 2009;104: 1802-1829.
30. Department of Veterans Affairs Hepatitis C Resource Center, Yee HS, Currie SL, Darling JM, et al. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office. Am J Gastroenterol. 2006;101:2360-2378.
31. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-1374.
32. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-2416.
33. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364: 1195-1206.
34. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014-1024.